GenomeKey raise Innovate UK funding to drive life-saving next-gen sepsis diagnostic

Posted by 

SETsquared Bristol

Our member GenomeKey, has secured an Innovate UK Biomedical Catalyst research award of £950,000 towards faster diagnosis and treatment of sepsis, one of the world’s most deadly diseases.

The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, save money, and save our antibiotics for the future.

The biotech company have raised £3.8 million to date in equity and non-dillutive funding sources.

Michael Roberts, CEO of GenomeKey said:

“Sepsis kills one in five people globally every year, and many of these deaths occur due to antibiotic resistance. GenomeKey believes in a future where these deaths can be avoided.

This project will enable us to get GenomeKey’s diagnostic for rapid bacterial species and antibiotic resistance identification closer to the people who need it, by placing our technology onto a portable microfluidic chip. We look forward to working with Innovate UK Biomedical Catalyst towards this goal.”

Recent News, Blogs and Stories

Celltris team - six people in manufacturing space smiling wearing black Celltris jumpers

Battery development startup Celltris receives £0.8 million investment

Bristol-based battery startup, Celltris has received a substantial boost in investment towards its mission to eliminate wasted internal space in lithium-ion cells, the rechargeable batteries used in electric vehicles. The...
Three people in a meeting with laptop and green Future Finance graphic overlay

New innovation skills & technology programme for financial services sector

From the rise of AI to ongoing changes in financial regulation, equitable access to financial services, to the opening of access to personal financial data, the financial services sector currently...
Neuronostics team - nine men and women smiling, wearing business casual

Medtech startup Neuronostics raises over £2 million

Multi-award-winning medtech startup, Neuronostics, has raised more than £2m in funding to develop its pioneering epilepsy diagnosis technology. The company received £2.1m in an oversubscribed seed funding round led by...


Fast track your technology business